Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million
1. Elutia sells its EluPro™ and CanGaroo® products for $88 million. 2. The sale funds NXT-41's development in breast reconstruction without shareholder dilution. 3. Elutia's strong platform positions it for significant future growth. 4. CEO states commitment to transforming the $1.5 billion breast reconstruction market. 5. Company updates expected during H.C. Wainwright Conference on September 10.